Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct’s new report, ”Egypt In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018” provides key market data on the Egypt In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Egypt In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Beckman Coulter, Inc., Abbott Laboratories, DiaSorin S.p.A, bioMerieux S.A. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Egypt In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 What is This Report About? 10
3 In Vitro Diagnostics In Egypt 11
3.1 In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, 2004-2018 11
3.2 In Vitro Diagnostics, Egypt, Company Share (2010-2011) 17
4 Clinical Chemistry In Egypt 19
4.1 Clinical Chemistry Overall Revenue, (2004-2018) 19
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 23
4.1.2 Urine Analysis, Revenue (2004-2018) 27
4.2 Clinical Chemistry Distribution Share (2010-2011) 29
4.3 Clinical Chemistry, Egypt, Company Share (2010-2011) 30
5 Genetic Testing In Egypt 32
5.1 Genetic Testing Overall Revenue, (2004-2018) 32
5.2 Genetic Testing Distribution Share (2010-2011) 36
5.3 Genetic Testing, Egypt, Company Share (2010-2011) 37
6 Haematology In Egypt 39
6.1 Haematology Overall Revenue, (2004-2018) 39
6.1.1 Haematology Reagents, Revenue, (2004-2018) 43
6.1.2 Immunohaematology, Revenue (2004-2018) 47
6.1.3 Haemostasis, Revenue (2004-2018) 51
6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 55
6.1.5 Haematology Cell Counters, Revenue (2004-2018) 59
6.2 Haematology Distribution Share (2010-2011) 63
6.3 Haematology, Egypt, Company Share (2010-2011) 64
7 Histology And Cytology In Egypt 66
7.1 Histology And Cytology Overall Revenue, (2004-2018) 66
7.2 Histology And Cytology Distribution Share (2010-2011) 70
7.3 Histology And Cytology, Egypt, Company Share (2010-2011) 71
8 Immuno Chemistry In Egypt 73
8.1 Immuno Chemistry Overall Revenue, (2004-2018) 73
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 77
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 81
8.1.3 Endocrinology Tests, Revenue (2004-2018) 85
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 89
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 93
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 97
8.2 Immuno Chemistry Distribution Share (2010-2011) 101
8.3 Immuno Chemistry, Egypt, Company Share (2010-2011) 102
9 Infectious Immunology In Egypt 104
9.1 Infectious Immunology Overall Revenue, (2004-2018) 104
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 108
9.2 Infectious Immunology Distribution Share (2010-2011) 112
9.3 Infectious Immunology, Egypt, Company Share (2010-2011) 113
10 Microbiology Culture In Egypt 115
10.1 Microbiology Culture Overall Revenue, (2004-2018) 115
10.1.1 Microbiology Analyzers, Revenue (2004-2018) 119
10.2 Microbiology Culture Distribution Share (2010-2011) 123
10.3 Microbiology Culture, Egypt, Company Share (2010-2011) 124
11 Overview of Key Companies in Egypt In Vitro Diagnostics Market 126
11.1 F. Hoffmann-La Roche Ltd. 126
11.1.1 Company Overview 126
11.2 Siemens Healthcare 126
11.2.1 Company Overview 126
11.3 Beckman Coulter, Inc. 127
11.3.1 Company Overview 127
11.4 Abbott Laboratories 127
11.4.1 Company Overview 127
11.5 DiaSorin S.p.A 128
11.5.1 Company Overview 128
11.6 bioMerieux S.A. 128
11.6.1 Company Overview 128
11.7 Alere Inc. 129
11.7.1 Company Overview 129
11.8 Becton, Dickinson and Company 129
11.8.1 Company Overview 129
11.9 Bio-Rad Laboratories, Inc. 130
11.9.1 Company Overview 130
11.10 Phadia AB 130
11.10.1 Company Overview 130
11.11 Grifols, S.A. 131
11.11.1 Company Overview 131
11.12 Mindray Medical International Limited 131
11.12.1 Company Overview 131
11.13 Ortho-Clinical Diagnostics Inc. 132
11.13.1 Company Overview 132
11.14 Sysmex Corporation 132
11.14.1 Company Overview 132
11.15 Qiagen N.V. 133
11.15.1 Company Overview 133
11.16 Horiba, Ltd. 133
11.16.1 Company Overview 133
11.17 PerkinElmer, Inc. 134
11.17.1 Company Overview 134
11.18 Gen-Probe Incorporated 134
11.18.1 Company Overview 134
11.19 Thermo Fisher Scientific Inc. 135
11.19.1 Company Overview 135
11.20 Olympus Corporation 135
11.20.1 Company Overview 135
11.21 Diagnostica Stago, Inc. 136
11.21.1 Company Overview 136
11.22 Life Technologies Corporation 136
11.22.1 Company Overview 136
11.23 Chembio Diagnostics, Inc. 137
11.23.1 Company Overview 137
11.24 Hologic, Inc. 137
11.24.1 Company Overview 137
11.25 Immucor, Inc. 138
11.25.1 Company Overview 138
12 Appendix 139
12.1 Global Markets Direct Research Methodology 139
12.2 Definitions of Markets Covered in the Report 140
12.2.1 In Vitro Diagnostics 140
12.3 Secondary Research 151
12.4 Primary Research 151
12.5 Models 152
12.6 Forecasts 152
12.7 Expert Panel Validation 152
12.8 Currency Conversion 153
12.9 Contact Us 153
12.10 Disclaimer 153

1.1 List of Tables
Table 1: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, 2004-2018 12
Table 2: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, Historic, 2004-2011 14
Table 3: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 16
Table 4: In Vitro Diagnostics, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 18
Table 5: Clinical Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 20
Table 6: Clinical Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 22
Table 7: Clinical Chemisty Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 24
Table 8: Clinical Chemisty Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 26
Table 9: Urine Analysis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 27
Table 10: Urine Analysis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 28
Table 11: Clinical Chemistry, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 29
Table 12: Clinical Chemistry, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 31
Table 13: Genetic Testing, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 33
Table 14: Genetic Testing, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 35
Table 15: Genetic Testing, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 36
Table 16: Genetic Testing, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 38
Table 17: Haematology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 40
Table 18: Haematology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 42
Table 19: Haematology Reagents, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 44
Table 20: Haematology Reagents, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 46
Table 21: Immunohaematology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 48
Table 22: Immunohaematology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 50
Table 23: Haemostasis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 52
Table 24: Haemostasis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 54
Table 25: Haematology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 56
Table 26: Haematology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 58
Table 27: Haematology Cell Counters, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 60
Table 28: Haematology Cell Counters, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 62
Table 29: Haematology, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 63
Table 30: Haematology, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 65
Table 31: Histology And Cytology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 67
Table 32: Histology And Cytology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 69
Table 33: Histology And Cytology, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 70
Table 34: Histology And Cytology, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 72
Table 35: Immuno Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 74
Table 36: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 76
Table 37: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 78
Table 38: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80
Table 39: Drugs of Abuse / Toxicology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82
Table 40: Endocrinology Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 84
Table 41: Endocrinology Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 86
Table 42: Immunochemistry Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 88
Table 43: Immunochemistry Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 90
Table 44: Therapeutic Drug Monitoring, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 92
Table 45: Therapeutic Drug Monitoring, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 94
Table 46: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 96
Table 47: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2004-2011 98
Table 48: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 100
Table 49: Immuno Chemistry, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 101
Table 50: Immuno Chemistry, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 103
Table 51: Infectious Immunology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 105
Table 52: Infectious Immunology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 107
Table 53: Infectious Immunology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 109
Table 54: Infectious Immunology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 111
Table 55: Infectious Immunology, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 112
Table 56: Infectious Immunology, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 114
Table 57: Microbiology Culture, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 116
Table 58: Microbiology Culture, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 118
Table 59: Microbiology Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 120
Table 60: Microbiology Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 122
Table 61: Microbiology Culture, Egypt, Distribution Share by Revenue ($m), USD Constant, 2010-2011 123
Table 62: Microbiology Culture, Egypt, Company Share by Revenue ($m), USD Constant, 2010-2011 125

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, 2004-2018 11
Figure 2: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, Historic, 2004-2011 13
Figure 3: In Vitro Diagnostics, Egypt, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 15
Figure 4: In Vitro Diagnostics, Egypt, Company Share (2010-2011) 17
Figure 5: Clinical Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 19
Figure 6: Clinical Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 21
Figure 7: Clinical Chemisty Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 23
Figure 8: Clinical Chemisty Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 25
Figure 9: Urine Analysis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 27
Figure 10: Urine Analysis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 28
Figure 11: Clinical Chemistry, Egypt, Company Share (%), 2011 30
Figure 12: Genetic Testing, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 32
Figure 13: Genetic Testing, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 34
Figure 14: Genetic Testing, Egypt, Company Share (%), 2011 37
Figure 15: Haematology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 39
Figure 16: Haematology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 41
Figure 17: Haematology Reagents, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 43
Figure 18: Haematology Reagents, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 45
Figure 19: Immunohaematology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 47
Figure 20: Immunohaematology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 49
Figure 21: Haemostasis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 51
Figure 22: Haemostasis, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 53
Figure 23: Haematology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55
Figure 24: Haematology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57
Figure 25: Haematology Cell Counters, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59
Figure 26: Haematology Cell Counters, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61
Figure 27: Haematology, Egypt, Company Share (%), 2011 64
Figure 28: Histology And Cytology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 66
Figure 29: Histology And Cytology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 68
Figure 30: Histology And Cytology, Egypt, Company Share (%), 2011 71
Figure 31: Immuno Chemistry, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 73
Figure 32: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 75
Figure 33: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 77
Figure 34: Disease Specific Immunochemistry, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 79
Figure 35: Drugs of Abuse / Toxicology, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 81
Figure 36: Endocrinology Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 83
Figure 37: Endocrinology Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 85
Figure 38: Immunochemistry Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 87
Figure 39: Immunochemistry Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 89
Figure 40: Therapeutic Drug Monitoring, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 91
Figure 41: Therapeutic Drug Monitoring, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 93
Figure 42: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 95
Figure 43: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2004-2011 97
Figure 44: Immunochemistry Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 99
Figure 45: Immuno Chemistry, Egypt, Company Share (%), 2011 102
Figure 46: Infectious Immunology, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 104
Figure 47: Infectious Immunology, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 106
Figure 48: Infectious Immunology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 108
Figure 49: Infectious Immunology Rapid Tests, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 110
Figure 50: Infectious Immunology, Egypt, Company Share (%), 2011 113
Figure 51: Microbiology Culture, Egypt, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 115
Figure 52: Microbiology Culture, Egypt, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 117
Figure 53: Microbiology Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 119
Figure 54: Microbiology Analyzers, Egypt, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 121
Figure 55: Microbiology Culture, Egypt, Company Share (%), 2011 124
Figure 56: Global Markets Direct Methodology 139